血清hsCRP、sTNFR2与2型糖尿病及大血管病变关系探讨

The relationship between serum hsCRP,sTNFR2 and type 2 diabetes mellitus with macrovascular complications

目的 探讨C 反应蛋白 (hsCRP)、肿瘤坏死因子α(TNF α)及其可溶性受体sTNFR2在 2型糖尿病 (T2 DM )及大血管病变发生发展中的作用。方法 酶联免疫吸附法 (ELISA)检测sTNFR2 ;放免法测定血清TNF α水平 ,化学发光法测定hsCRP含量。结果 证实T2 DM血清TNF α、sTNFR2与hsCRP水平明显增高 ,合并大血管病变组比单纯T2 DM组更高。血清sTNFR2、hsCRP可作为T2 DM心血管病变危险因子。结论 血清sTNFR2、hsCRP可反映机体炎症活性 ,在胰岛素抵抗及 2型糖尿病大血管病变发病机制中起一定作用 ,抗TNF α治疗可能是一种新治疗措施。

Objective To study the relationship between tumor necrosis factor,soluble fraction of tumor necrosis factor receptor 2(sTNFR2) and C-reactive protein(CRP) in type 2 diabetic patients with or without macrovascular complications. Methods Researching 56 with patients type 2 diabetic and 30 normal individuals in this study.sTNFR2 was determined by enzyme-linked immunosorbent assay.TNF-α was determined by RIA. hsCRP was measured by immunometric assay.Results The serum levels of sTNFR2 and hsCRP were increased in both type 2 diabetic groups. The serum levels of sTNFR2 and hsCRP in type 2 diabetic patients with macrovascular complications were significantly higher than those in simple diabetes group. The serum sTNFR2,hsCRP were positive factors in the progress of diabetic macrovascular complications.Conclusions sTNFR2,hsCRP may be useful markers of systemic inflammation. The serum levels of sTNFR2 may play role in insulin resistance and the pathogenesis of diabetic macrovascular complications.Anti-TNFα therapy may be a new way to prevent the growth and development of diabetic macrovascular complications.